David Drosick, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
West Virginia University
Medical School
University of Kentucky
Residency
University of Kentucky
Fellowship
American Board of Internal Medicine - Oncology
OH State Medical License: 1991 - 2019
KY State Medical License: 1986 - 2018
American Board of Internal Medicine: Internal Medicine
American Board of Internal Medicine: Medical Oncology
TriHealth Bethesda North Hospital
Languages: English/Spanish
+1 513-865-1111
10500 Montgomery Rd
Read MoreTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley, D. A.,Arrowsmith, E. R.,Daniel, B. R.,Eakle, J.,Brufsky, A.,Drosick, D. R.,Kudrik, F.,Bosserman, L. D.,Keaton, M. R.,Goble, S. A.,Bubis, J. A.,Priego, V. M.,P...; Breast Cancer Res. Treat.. 2017 May 17
See more >>Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Yardley, D. A.,Dickson, N.,Drosick, D.,Earwood, C.,Inhorn, R.,Murphy, P.,Hainsworth, J. D.; Clin. Breast Cancer. 1900 Jan 01.
See more >>Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Yardley, D. A.,Hart, L.,Waterhouse, D.,Whorf, R.,Drosick, D. R.,Murphy, P.,Badarinath, S.,Daniel, B. R.,Childs, B. H.,Burris, H.; Breast Cancer Res. Treat.. 2013 Nov 21
See more >>